Patent intelligence · US
US 10105316
Inhalation compositions comprising muscarinic receptor antagonist
Inhalation compositions comprising muscarinic receptor antagonist
Patent details — US 10105316
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 23, 2018
- Expiration
- Oct 18, 2038
- Applicant
- ARVEN ILAC SANAYI VE TICARET A.S.
- Claims
- 47
- CPC classes
- A61K, A61K31/137, A61K31/138, A61K31/167
Quick answer
US 10105316 (Inhalation compositions comprising muscarinic receptor antagonist) is held by ARVEN ILAC SANAYI VE TICARET A.S.. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARVEN ILAC SANAYI VE TICARET A.S.
- Grant date
- Expiration
- Claims
- 47
- CPC classes
- A61K, A61K31/137, A61K31/138, A61K31/167, A61K31/24, A61K31/27
More from ARVEN ILAC SANAYI VE TICARET A.S.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 10105316?
US 10105316 (Inhalation compositions comprising muscarinic receptor antagonist) is held by ARVEN ILAC SANAYI VE TICARET A.S.. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10105316?
ARVEN ILAC SANAYI VE TICARET A.S. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 10105316 expire?
Our index shows an expiration date of Oct 18, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.